Avoro Capital Advisors logo

Avoro Capital Advisors

North America, New York, United States, New York

Description

Avoro Capital Advisors is a global life sciences investment firm.

Investor Profile

Avoro Capital Advisors has backed more than 19 startups, with 3 new investments in the last 12 months alone. The firm has led 4 rounds, about 21% of its total and boasts 14 exits across its portfolio.

Investment Focus Highlights

  • Concentrates on Post Ipo Equity, Series B, Series C rounds (top funding stages).
  • Majority of deals are located in United States, Ireland, Switzerland.
  • Strong thematic focus on Biotechnology, Health Care, Therapeutics.
  • Led 1 rounds in the past year.

Stage Focus

  • Post Ipo Equity (47%)
  • Series B (21%)
  • Series C (21%)
  • Series D (5%)
  • Series A (5%)

Country Focus

  • United States (79%)
  • Ireland (5%)
  • Switzerland (5%)
  • Denmark (5%)

Industry Focus

  • Biotechnology
  • Health Care
  • Therapeutics
  • Biopharma
  • Life Science
  • Medical
  • Oncology
  • Pharmaceutical
  • Information Technology
  • Manufacturing
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Avoro Capital Advisors frequently co-invest with?

OrbiMed
North America, New York, United States, New York
Co-Investments: 6
Wellington Management
North America, Massachusetts, United States, Boston
Co-Investments: 5
Surveyor Capital
North America, Illinois, United States, Chicago
Co-Investments: 5
CA
North America, Massachusetts, United States, Boston
Co-Investments: 5
AC
North America, California, United States, Belmont
Co-Investments: 6
RA Capital Management
North America, Massachusetts, United States, Boston
Co-Investments: 7
Co-Investments: 5
Vivo Capital
North America, California, United States, Palo Alto
Co-Investments: 5
Logos Capital
North America, California, United States, San Francisco
Co-Investments: 5
Janus Henderson Investors
Europe, England, United Kingdom, London
Co-Investments: 5

What are some of recent deals done by Avoro Capital Advisors?

Hemab

Copenhagen, Hovedstaden, Denmark

Hemab is a clinical-stage biotech company that develops prophylactic biologic therapies for underserved bleeding and thrombotic.

BiotechnologyLife ScienceMedicalPharmaceutical
Series COct 27, 2025
Amount Raised: $157,000,000
Aadi Bioscience

Pacific Palisades, California, United States

Aadi Bioscience develops a potentially mTOR inhibitor for targeted patient populations in oncology and cardiovascular diseases.

BiopharmaBiotechnologyLife ScienceOncology
Post Ipo EquityMar 4, 2025
Amount Raised: $100,000,000
Aadi Bioscience

Pacific Palisades, California, United States

Aadi Bioscience develops a potentially mTOR inhibitor for targeted patient populations in oncology and cardiovascular diseases.

BiopharmaBiotechnologyLife ScienceOncology
Post Ipo EquityDec 20, 2024
Amount Raised: $100,000,000

Ottimo Pharma develops innovative cancer therapies using PD1-VEGFR2 antibodies.

BiotechnologyHealth CarePharmaceutical
Series ADec 19, 2024
Amount Raised: $140,000,000
Krystal Biotech

Pittsburgh, Pennsylvania, United States

Krystal Biotech provide significant clinical benefit for patients suffering from rare debilitating disorders..

BiopharmaBiotechnologyHealth Care
Post Ipo EquityMay 21, 2023
Amount Raised: $160,000,000
Aadi Bioscience

Pacific Palisades, California, United States

Aadi Bioscience develops a potentially mTOR inhibitor for targeted patient populations in oncology and cardiovascular diseases.

BiopharmaBiotechnologyLife ScienceOncology
Post Ipo EquitySep 22, 2022
Amount Raised: $72,500,000
Kymera Therapeutics

Cambridge, Massachusetts, United States

Kymera Therapeutics is a biotechnology company that specializes in the field of targeted protein degradation.

BiotechnologyHealth CareMedicalTherapeutics
Post Ipo EquityAug 19, 2022
Amount Raised: $150,000,000
Aadi Bioscience

Pacific Palisades, California, United States

Aadi Bioscience develops a potentially mTOR inhibitor for targeted patient populations in oncology and cardiovascular diseases.

BiopharmaBiotechnologyLife ScienceOncology
Post Ipo EquityAug 26, 2021
Amount Raised: $154,999,876
Tango Therapeutics

Cambridge, Massachusetts, United States

Tango Therapeutics is a biotechnology company that is developing next generation cancer therapies.

BiotechnologyHealth CareMedicalTherapeutics
Post Ipo EquityAug 11, 2021
Amount Raised: $186,000,000
Nuvalent

Cambridge, Massachusetts, United States

Nuvalent is a biotechnology company that develops targeted therapies for clinically proven kinase targets in cancer.

BiotechnologyLife ScienceTherapeutics
Series BMay 11, 2021
Amount Raised: $135,000,000

Find More Investors Like Avoro Capital Advisors

Discover similar investors in our database and build your perfect investor list.

Need help with your fundraising strategy?Read our fundraising guides

Avoro Capital Advisors | Pipeseed